Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia P388.
The coordinated gold compound, 2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S-triethylphosphine-gold (auranofin) was found to be effective in increasing the life span of C57BL x DBA/2 F1 mice inoculated with the lymphocytic leukemia P388. A number of dose schedules were used, the lowest dose being 6 mg/kg every fourth day and the highest dose being 6.0 mg/kg twice daily for 9 days; the lowest and highest doses produced treated versus control ratios of 140 and 220%, respectively. All treatment groups achieved the minimum treated versus control ratio of 125%. Animal weights remained stable at twice-daily and high-dose-daily regimens. Increased life span and weight changes were both found to correlate with drug concentration and/or dose frequency.
D000818:Animals; D000970:Antineoplastic Agents; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D006046:Gold / Q000031:analogs & derivatives*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D051379:Mice; D010720:Phosphines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010720:Phosphines; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold